Patients who are immunocompromised (IC) are at increased risk of Clostridium diffi cile infection (CDI), which has increased to epidemic proportions over the past decade. Fecal microbiota transplantation (FMT) appears effective for the treatment of CDI, although there is concern that IC patients may be at increased risk of having adverse events (AEs) related to FMT. This study describes the multicenter experience of FMT in IC patients.
INTRODUCTION
Clostridium diffi cile infection (CDI) is responsible for 15 -25 % of nosocomial antibiotic-associated diarrhea ( 1 ) and has increased rapidly in the past decade ( 2 ) to an incidence of 10.4 cases per 1,000 patient admissions ( 3 ) . Recurrence is a common management problem and occurs in up to 20 % of patients aft er initial CDI treatment ( 4 ) . Current guidelines recommend a tapering course of vancomycin aft er a second recurrence; however, up to 60 % of patients do not respond to this treatment strategy or develop further recurrence aft er the vancomycin is stopped ( 5 ) .
Initially described for treatment of pseudomembranous enterocolitis in 1958 ( 6 ) , fecal microbiota transplant (FMT) has proven to be effi cacious and safe in numerous case series ( 7 ) and a recently published clinical trial ( 8 ) . Th e use of FMT among immunocompromised (IC) patients with CDI has been limited due to concerns about its safety in this population. Published guidelines recommend avoidance of fecal transplant in solid organ transplant (SOT) recipients because of the theoretic potential for infection ( 9 ) and caution even against the use of probiotics in IC hosts because of the rare complication of superinfection (including bloodstream infections), which has been reported from these " nonpathogenic " organisms ( 10, 11 ) . A recent guidance issued by the FMT working group specifi ed that considerations for increased risk of adverse events (AEs) should be given to patients on major immunosuppressive agents and patients with decompensated liver cirrhosis, advanced HIV / AIDS, recent bone marrow transplant, or other causes of severe immunodefi ciency ( 12 ) . Furthermore, the Food and Drug Administration / Center for Biologics Evaluation and Research recommended that patients who were IC for any reason be excluded from the fi rst randomized trial of FMT in this country ( 13 ) . Successful treatment of CDI in two SOT recipients was recently described ( 14 ) ; however, to date, no study has systematically investigated the safety and effi cacy of FMT in a larger cohort of IC patients. We and colleagues at other medical centers off ering FMT have treated a number of IC patients with FMT. By this collective experience we aim to describe rates of CDI cure in this population as well as AEs experienced by IC patients aft er FMT.
METHODS
We performed a retrospective study of IC patients with CDI who underwent FMT at 16 medical centers nationally and internationally. Th e study was approved by the Lifespan Institutional Review Board and the protocol was then made available to any center participating in the study for institution-specifi c Institutional Review Board approval. Th e methods used to administer FMT diff ered among sites, although most (12 of 16) exclusively used an endoscopic lower gastrointestinal route of administration. Informed consent had been obtained from all patients before FMT. A 32-item data collection form was developed, which elicited demographic data, CDI characteristics, and pre-and post-FMT data for each patient. Patients were included if they were IC and had undergone FMT to treat recurrent, refractory, severe, or complicated CDI unresponsive to standard therapy. Defi nitions used to classify recurrent, severe, and complicated CDI for this study were based on the recently published American College of Gastroenterology ( 11 ) and working group ( 12 ) At least 12 weeks of post-FMT follow-up data were required for the patient ' s data to be included in the analysis. We assumed that all recurrences ( 15 ) and most short-term complications of FMT (such as infection) would have occurred within this time period. We included patients who were IC at the time of FMT as a result of one or more of the following: HIV infection (any CD4 count), AIDS-defi ning diagnosis or CD4 < 200 / mm 3 , inherited or primary immune disorders, and immunodefi cient or immunosuppressed from a medical condition / medication including current or recent ( < 3 mos) treatment with anti-neoplastic agent or immunosuppressant medications (including but not limited to monoclonal antibodies to B and T cells, anti-tumor necrosis factor agents, glucocorticoids, antimetabolites (azathioprine, 6-mercaptopurine, methotrexate), calcineurin inhibitors (tacrolimus, cyclosporine), and mycophenolate mofetil).
Data collected included demographic information, reason for IC status, treatment with immunosuppressant medication, other signifi cant medical conditions, CDI treatments before and peri-FMT, indication for FMT (recurrent, refractory, or severe / complicated CDI), post-FMT mortality and hospitalizations, post-FMT AEs and serious adverse events (SAEs), and outcomes (CDI recurrence post FMT, need for colectomy, and response to second FMT if required). Sixteen centers submitted data collection forms for 99 patients. Patients were excluded from analysis if FMT was conducted for reasons other than CDI, if they did not meet the criteria for IC or if they did not have a minimum of 12 weeks post-FMT follow-up.
Th e primary outcomes were CDI cure and any SAEs or AEs within 12 weeks post FMT. Cure was defi ned as absence of diarrhea, or marked reduction in stool frequency without the need for further anti-CDI therapy. Th is defi nition of cure was used in recent CDI clinical trials ( 16 ) and, consistent with published practice guidelines ( 1, 11 ) , stool was not routinely tested for C. diffi cile toxin to confi rm cure at most centers. AEs were defi ned as any untoward medical occurrence in a patient to whom FMT was administered. Th e AE did not necessarily need to have a causal relationship with the treatment and thus we included unfavorable signs or symptoms or disease temporally associated with the use of FMT, whether or not related to the FMT. AEs could be clinically signifi cant changes from baseline physical exam, laboratory tests, or other diagnostic investigations, complications related to the procedure used to administer FMT, or new events or pre-existing conditions that became aggravated or worsened in severity or frequency within 12 weeks post FMT. SAEs were defi ned as any death, life-threatening experience, unplanned hospitalization, or important medical event within 12 weeks aft er FMT. AEs and SAEs were determined to be related, probably or possibly, or unrelated to FMT. Secondary outcomes were CDI recurrence, need for colectomy, and response to repeat FMT. Cure rates and percentages were calculated aft er one FMT and more than one FMT for the population. Rates and percentages were also calculated for SAEs, AEs, and infl ammatory bowel disease (IBD) fl ares.
RESULTS

Study patient characteristics
Data collection forms were completed for 99 patients who had received FMT at one of the study centers. Of these, 19 were excluded from analysis because they had undergone FMT for treatment of IBD alone (15 patients), did not meet criteria for IC (2 patients), or were lost to follow-up before having their 12-week post-FMT follow-up (2 patients). Eighty patients were included in the fi nal analysis ( Table 1a ) . Th e study population included similar numbers of men (42, 52 % ) and women (38, 48 % ) . Th e majority of these patients were adults (75 of 80, 94 % ) and the mean age of the adults treated was 53 years (range: 20 -88 years). Reasons for IC included IBD patients treated with immunosuppressive agents (36, 45 % ), SOT recipients (19, 24 % ), and patients IC because of severe or end-stage chronic medical conditions (15, 19 % ) . In addition, there were seven (9 % ) patients with cancer who were receiving antineoplastic agents concurrently or in the 3 months before FMT, and three (3 % ) patients had HIV / AIDs. Specifi c immunosuppressant agents used, indications, and numbers of patients exposed are listed in Safety . SAEs were observed in 12 (15 % ) patients within 12 weeks post FMT ( Table 2 ) . Two deaths occurred. One patient, whose diarrhea ceased aft er FMT, died 13 days post-FMT secondary to progressive pneumonia, for which she was treated with antibiotics before and aft er FMT. Th e other, a SOT recipient with advanced esophageal cancer, cachexia, and ongoing diarrhea from CDI unresponsive to vancomycin and metronidazole, died of respiratory failure 1 day post FMT as a result of a witnessed aspiration at the time of sedation for the colonoscopy used to administer the FMT. Th ere were 10 hospitalizations within 12 weeks of FMT. One patient was hospitalized with self-limited abdominal pain, which occurred aft er the colonoscopy used to administer FMT and was thus related to FMT. Th ree hospitalizations were unrelated to FMT and one case of infl uenza was probably unrelated as the donor did not develop infl uenza within the follow-up period. Four patients were hospitalized with fl ares of IBD possibly related to FMT. One catheter line infection requiring hospitalization occurred and was probably unrelated to FMT. Th ere were no infectious complications directly attributable to FMT. Th ree deaths were reported outside of the 12-week post-FMT period and were not considered as SAEs. All occurred more than 6 months aft er FMT and were related to chronic progressive illnesses unrelated to CDI. We observed 12 (15 % ) patients with AEs ( Table 2 ). Of these, four were related, fi ve were possibly related, and three were unrelated to FMT. Th ree patients underwent colectomy, although none were for CDI. One patient with ulcerative colitis (UC) had a colectomy COLON / SMALL BOWEL Fecal Microbiota Transplant for Treatment of C. difficile these patients at the time of FMT ranged from mild to severe. However, all are known to have had severe (and oft en refractory) disease leading up to FMT and, despite short-term complications, three benefi ted from FMT in terms of their CDI and the course of their IBD. It is not possible to determine whether these fl ares were attributable to FMT, CDI, or progression of the underlying disease. However, IBD fl are aft er FMT to treat CDI in a patient with previously quiescent UC has been reported ( 33 ) and fevers along with temporary elevations of C-reactive protein levels have been described in small series of UC patients treated with FMT for IBD ( 34, 35 ) . Certainly, prospective studies regarding safety and effi cacy of FMT in this population are warranted.
Physicians may be reluctant to prescribe FMT in IC patients presuming they are " high risk, " although there has not previously been evidence either for or against this belief in this population. In fact, patients with recurrent CDI have been shown to have a marked expansion of members of the Enterobacteriaceae family of Proteobacteria in their gut microbiota ( 36 -38 ) , which are frequently relatively invasive pathobionts that may be responsible for other infectious complications in these patients ( 39 ) . In contrast, FMT leads to restoration of dominance of Bacteroidetes and Firmicutes in the distal gut microbiota. It is reasonable to expect that normalized gut microbial ecology should improve colonization resistance to potential pathogens in IC patients.
Th is study has several weaknesses. Because of the retrospective design, data collection may be incomplete. Moreover, patients were not solicited for AEs, which may be underestimated. Detailed clinical information regarding disease history, extent, and severity, including endoscopic and histologic fi ndings before and aft er FMT, for IBD patients was not collected. Diarrheal symptoms are a common symptom in IBD and the high prevalence of IBD could have distorted the effi cacy rate in this population, given the symptom-based criteria we used to defi ne cure. Nevertheless, rates of cure aft er FMT were high in this subset of patients. Other potential confounding factors such as the discontinuation of chemotherapy or treatment changes in IBD patients could also have had an impact on diarrheal symptoms. Th e population treated is very heterogenous. Collecting more data on the course of immunocompromising illnesses in each of these patients would have been helpful in identifying potential confounders and stratifying patients as sickest to healthiest among this IC group. Th e multicenter design made standardization of data points challenging, yet the FMTperforming clinicians followed each patient closely, and all centers provided suffi cient details to answer the 32-item survey tool required to analyze the primary outcomes. Th ere is no consensus guideline for the administration of FMT in terms of the donor screening, amount of stool infused, route of administration, or follow-up evaluations. However, this study, performed at multiple sites, each with its own FMT protocol, supports an overall curative eff ect seen among IC patients despite practice variation. Classifi cation of CDI was based on specifi c clinical criteria, although the data collection survey did not distinguish between severe and complicated CDI or allow submitting centers to specify which criteria for severe or complicated disease were fulfi lled. Patients may have been classifi ed as severe on the basis of leukocytosis or low with patients IC because of other conditions (18 % SAEs; 16 % AEs) P ≤ 0.3224.
DISCUSSION
IC patients are particularly at risk of CDI. C. diffi cile is the most common cause of bacterial diarrhea in persons with HIV infection and has its highest incidence in those with advanced HIV disease / AIDS ( 17 ) . Organ transplant recipients are also observed to suff er higher frequency of CDI. Retrospective case series of patients aft er SOT report an overall CDI incidence of 3.5 -16 % in kidney transplant recipients and is as high as 31 % in lung transplant recipients ( 9 ) . Furthermore, 20 % of SOT patients who acquired CDI did not have any recent antibiotic exposure, which suggests that IC status may be an independent risk factor for CDI ( 18 ) . Increased length of stay in hospitals and extendedcare facilities in addition to multiple exposures to broad-spectrum antibiotics increases the risk of CDI in this population of patients ( 19, 20 ) . However, disruptions of both the innate and adaptive immune responses are additional factors, as the signaling pathways involved in the recruitment of neutrophils mitigate infl ammation in acute infection ( 21 ) and patients with increased anti-toxin A and B IgG antibodies may be at decreased risk of suff ering recurrences of CDI compared with those who have reduced levels of the antibody ( 22, 23 ) .
CDI presents an especially diffi cult challenge in patients with underlying IBD, which is associated with a disrupted mucosal barrier in the gut, altered mucosal immunity, and systemic immunosuppression with medications. IBD patients develop CDI at a threefold higher rate compared with the general population and have an estimated 10 % life time chance to contract C. diffi cile ( 24, 25 ) . Increases in hospitalizations, mortality, and colectomy rates over the past decade in CDI-IBD patients are well demonstrated ( 26 -29 ) . Up to 19 % of the patients with an IBD fl are test positive for C. diffi cile ( 30 ) . Immunosuppressive medications commonly used in this patient population multiply the risk of CDI; above all, corticosteroids confer a threefold increase in CDI and twofold increase in mortality ( 31, 32 ) .
In this multicenter series, 89 % of IC patients achieved symptom resolution aft er FMT for C. diffi cile infection and most CDI resolved aft er a single FMT. Rates of cure were similar to those observed in previous studies ( 7, 8 ) . Th is study is the fi rst to systematically report safety outcomes in FMT and the fi rst to address the question of effi cacy and safety of FMT for CDI in IC patients. IC patients have previously been excluded from controlled FMT studies ( 8, 13 ) because of concern about bacterial translocation and infection. In these 80 patients who underwent FMT at 16 centers, there were no deaths or documented infections that occurred aft er FMT as a result of the transplanted microbiota itself. One death occurred as a result of the procedure used to re-administer a second FMT in a severely ill patient.
It is noteworthy that 14 % of the patients with IBD experienced complications post FMT in the form of a disease exacerbation; three of whom were treated with steroids and one patient required a colectomy within 1 month of FMT. Colonic disease activity in COLON / SMALL BOWEL Kelly et al.
albumin (not necessarily sepsis or organ failure). Furthermore, it is unknown at what time point FMT was performed in some of these severe patients, although most of the centers in this study perform FMT aft er a course of vancomycin when patients have improved clinically but are at risk for further recurrence. Th e fact that the majority of these FMTs were performed as outpatient procedures supports that most patients in this series were not acutely ill at the time of FMT. Ultimately, a prospective cohort study of patients with complex CDI or a matched case -control series would be reasonable to further investigate the use of FMT for CDI in IC patients, while minimizing some of these biases.
FMT is not without risk, which may be greater in acutely ill patients. In the experience of several of the coauthors, there is limited effi cacy to a single FMT performed at the time of acute CDI, and delaying FMT or performing a second FMT aft er the patient has fi nished a course of anti-CDI therapy may be the best course ( 40 ) . We believe it is prudent to consider less invasive means of administering FMT (such as enema or unsedated sigmoidoscopy) in patients with severe or complicated CDI or signifi cant comorbidities. Withholding FMT and / or administering vancomycin indefi nitely to prevent further CDI recurrence is another option when treating patients with a limited life expectancy in whom the risk of FMT may outweigh benefi ts. In conclusion, this study showed that FMT appears to be a safe and eff ective treatment for recurrent, refractory, or severe CDI in this high-risk population of IC patients. '
